cellvie Presents at CEOT 2026

Scottsdale, Arizona – February 26, 2026 – Cellvie was invited to present at the AST Cutting Edge of Transplantation (CEOT) meeting, where the company showcased its novel approach of mitochondria transplantation for the treatment of ischemia-reperfusion injury.

CEOT is organized by the American Society of Transplantation, one of the leading professional organizations in the field of organ transplantation. The meeting brings together top clinicians, researchers, and industry experts to discuss innovations shaping the future of transplantation.

During the presentation, cellvie showcased new data demonstrating the protective effects of mitochondria transplantation in mitigating ischemia-reperfusion injury in large animal models of kidney transplantation. The ability of mitochondria, when administered during reperfusion, to treat ischemia-reperfusion injury has now been reproduced consistently across acute models of kidney ischemia as well as transplant studies, reinforcing confidence in the therapeutic potential of this approach.

"We were very encouraged by how well the data was received," said Dr. Alexander Schueller, co-Founder and CEO of cellvie. "There was strong interest in our work from both clinicians and industry experts attending the meeting, which underscores the significant need for new solutions in transplantation medicine."

The positive feedback and engagement from the audience further highlight the growing relevance of mitochondrial therapies in addressing critical challenges in organ transplantation.

cellvie would like to thank the American Society of Transplantation for organizing this impactful event and for the invitation to present. The team looks forward to continuing the discussion and returning to CEoT in the future.

About cellvie

Headquartered in Zürich, cellvie is a Harvard Medical School spin out and pioneer in mitochondria-based therapeutics, developing allogeneic cell-line derived frozen mitochondria as a scalable and shelf life stable medicinal product. The team is focusing on ischemia-reperfusion injury as the technology’s first application - a thus far intractable disease pathology and leading cause of death arising in heart attacks, stroke, or organ transplantation. cellvie believes in the platform potential of mitochondria honing a pipeline of applications in the fields of cell and gene therapy and longevity.

Back to news